statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Equillium reports inducement grant under Nasdaq listing rule

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on April 1...

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Equillium (NASDAQ:EQ - Free Report) had its target price boosted by HC Wainwright from $4.00 to $5.00 in a research note issued to investors on Tuesday morning, Benzinga reports. HC Wainwright...

Equillium (NASDAQ:EQ) Given New $5.00 Price Target at HC Wainwright

Leerink Partners analyst Thomas Smith has maintained their bullish stance on EQ stock, giving a Buy rating yesterday. Thomas Smith has given his Bu...

Buy Rating Affirmed for Equillium on Strong Clinical Data and Potential Financial Upsides

Equillium announces topline data from Type B portion of EQUALISE study

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline...

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Equillium reports Q4 EPS (7c) vs. 8c last year

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will...

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March, 2017 and is headquartered in La Jolla, CA.

Volume	130,536.00
52-Wk High	$3.25
52-Wk Low	$0.45

EQ Equillium Inc

About

Feed

News

Sentiment

Earnings

Fundamentals